Skin and Serum
Ingredients

Nivea Sales Decline 4.9% as Beiersdorf's Derma Segment Grows

Beiersdorf's Q3 2026 group sales fell 1.3% to €2.4bn, with Nivea's 4.9% drop contrasting sharply against 10.6% growth for its Eucerin and Aquaphor derma brands amid trade tensions and premium demand.

Beiersdorf's Q3 2026 group sales fell 1.3% to €2.4bn, with Nivea's 4.9% drop contrasting sharply against 10.6% growth for...

Beiersdorf reported a 1.3% decline in Q3 2026 group net sales to €2.4bn amid broader consumer weakness. The consumer business segment saw sales dip 0.7% year-on-year, highlighting a challenging quarter for the skincare giant. For the first nine months of the year, group net sales reached €7.3bn, representing an organic decline of 2.8%.

Derma Segment Growth

The derma category led with 10.6% organic growth driven by Eucerin and Aquaphor expansions. This strong performance was supported by Aquaphor's move into body care and the launch of a new Eucerin solution for acne-prone skin. The healthcare business also grew, posting a 5.7% sales increase in the quarter attributed to wound care innovation.

Meanwhile, the luxury brand La Prairie saw sales increase by 8.5%, with significant growth noted in China.

Nivea's Value Proposition Challenge

Nivea's 4.9% sales drop reflects trade tensions and the difficulty of maintaining value-for-money positioning. The brand, positioned as a value-for-money option, faced headwinds while premium derma brands like Eucerin thrived. CEO Vincent Warnery highlighted the challenge, stating, "You have, particularly in the mass market, consumers willing to have value for money proposals, and this is why Nivea has to fight and maintain."

Despite the quarterly decline, Nivea's consumer sales increased globally during the period, reflecting demand as part of its ongoing turnaround plan. External pressures added complexity. The Middle East war caused higher logistics costs, with potential oil price pressure above US$100. CFO Astrid Hermann noted, "I would certainly suggest that it has caused quite a bit of headache to our teams, particularly in the supply chain," though she confirmed no significant operational disruption.

Premium Innovation Strategy

Beiersdorf is leveraging premium derma success and microbiome research to offset Nivea's challenges. The company unveiled a new Eucerin acne treatment based on two decades of microbiome research. It also extended Nivea's longevity offerings with an epigenetics eye serum featuring cryogenic technology.

The company anticipates that Nivea's sell-in headwinds and destocking will gradually fade by the end of 2026. Its broader turnaround plan focuses on innovation, reinforcing its value-for-money proposition, and ensuring local relevance. This includes adapting the emerging market Face+ concept for European needs and a five-year Tour de France partnership for Nivea Sun starting in 2027.

Looking ahead, full-year 2026 guidance expects a low-single-digit organic sales decline for the consumer business. The group's EBIT margin excluding special factors is projected to reach a minimum of 11%. Beiersdorf aims to reduce its reliance on Nivea through strategic acquisitions.

Related coverage

More from Ingredients